Photobiomodulation is poised for a transformative shift in clinical application, with multicenter randomized trials targeting chronic pain, myopia progression, and post-stroke cognition set to launch. Standardized device parameters and a focus on biphasic dose-response curves aim to establish safe upper limits, enhancing the treatment's applicability across neurological, ophthalmological, and immunological fields. As evidence of its low-risk effectiveness strengthens, this therapy is on track to transition from experimental proof-of-concept to integration in mainstream medical practice.